Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Vidarabine"" wg kryterium: Temat


Tytuł :
Adoptive cell therapy using tumor-infiltrating lymphocytes for melanoma refractory to immune-checkpoint inhibitors.
Autorzy :
Hirai I; Department of Dermatology, Keio University School of Medicine, Tokyo, Japan.
Funakoshi T; Department of Dermatology, Keio University School of Medicine, Tokyo, Japan.
Kamijuku H; Institute for Advanced Medical Research, Division of Cellular Signaling, Keio University School of Medicine, Tokyo, Japan.
Fukuda K; Department of Dermatology, Keio University School of Medicine, Tokyo, Japan.
Mori M; Department of Dermatology, Keio University School of Medicine, Tokyo, Japan.
Sakurai M; Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Koda Y; Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Kato J; Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Mori T; Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Watanabe N; Center for Transfusion Medicine and Cell Therapy, Keio University School of Medicine, Tokyo, Japan.
Noji S; Institute for Advanced Medical Research, Division of Cellular Signaling, Keio University School of Medicine, Tokyo, Japan.
Yaguchi T; Institute for Advanced Medical Research, Division of Cellular Signaling, Keio University School of Medicine, Tokyo, Japan.
Iwata T; Institute for Advanced Medical Research, Division of Cellular Signaling, Keio University School of Medicine, Tokyo, Japan.; Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
Ohta S; Institute for Advanced Medical Research, Division of Cellular Signaling, Keio University School of Medicine, Tokyo, Japan.
Fujita T; Institute for Advanced Medical Research, Division of Cellular Signaling, Keio University School of Medicine, Tokyo, Japan.
Tanosaki R; Center for Transfusion Medicine and Cell Therapy, Keio University School of Medicine, Tokyo, Japan.
Handa M; Center for Transfusion Medicine and Cell Therapy, Keio University School of Medicine, Tokyo, Japan.
Okamoto S; Institute for Advanced Medical Research, Division of Cellular Signaling, Keio University School of Medicine, Tokyo, Japan.
Amagai M; Department of Dermatology, Keio University School of Medicine, Tokyo, Japan.
Kawakami Y; Institute for Advanced Medical Research, Division of Cellular Signaling, Keio University School of Medicine, Tokyo, Japan.; Department of Immunology, School of Medicine, International University of Health and Welfare, Chiba, Japan.
Pokaż więcej
Źródło :
Cancer science [Cancer Sci] 2021 Aug; Vol. 112 (8), pp. 3163-3172. Date of Electronic Publication: 2021 Jun 30.
Typ publikacji :
Clinical Trial; Journal Article
MeSH Terms :
Cyclophosphamide/*administration & dosage
Interleukin-2/*administration & dosage
Lymphocytes, Tumor-Infiltrating/*transplantation
Melanoma/*therapy
Vidarabine/*analogs & derivatives
Administration, Intravenous ; Cell Culture Techniques ; Cyclophosphamide/therapeutic use ; Feasibility Studies ; Gene Regulatory Networks ; Humans ; Immune Checkpoint Inhibitors ; Immunotherapy, Adoptive ; Lymphocytes, Tumor-Infiltrating/cytology ; Male ; Melanoma/genetics ; Melanoma/immunology ; Middle Aged ; Pilot Projects ; Transplantation Conditioning ; Treatment Outcome ; Vidarabine/administration & dosage ; Vidarabine/therapeutic use
Czasopismo naukowe
Tytuł :
A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients.
Autorzy :
Martínez Sánchez MP; Servicio de Hematología y Hemoterapia, Hospital Universitario 12 de Octubre, UCM, CNIO, CIBERONC, Madrid, Spain.
Megías-Vericat JE; Servicio de Farmacia, Área del Medicamento, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
Rodríguez-Veiga R; Servicio de Hematología y Hemoterapia, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
Vives S; Servicio de Hematología y Hemoterapia, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain.
Bergua JM; Servicio de Hematología y Hemoterapia, Hospital San Pedro de Alcántara, Cáceres, Spain.
Torrent A; Servicio de Hematología y Hemoterapia, ICO-Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain.
Suárez-Varela S; Servicio de Hematología y Hemoterapia, Hospital San Pedro de Alcántara, Cáceres, Spain.
Boluda B; Servicio de Hematología y Hemoterapia, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
Martínez-López J; Servicio de Hematología y Hemoterapia, Hospital Universitario 12 de Octubre, UCM, CNIO, CIBERONC, Madrid, Spain.
Cano-Ferri I; Servicio de Hematología y Hemoterapia, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
Acuña-Cruz E; Servicio de Hematología y Hemoterapia, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
Torres-Miñana L; Servicio de Hematología y Hemoterapia, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
Martín-Herreros B; Grupo de investigación en Hematología, Instituto de Investigación Sanitaria La Fe (IISLAFE), Valencia, Spain.
Serrano A; Servicio de Hematología y Hemoterapia, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
Sempere A; Servicio de Hematología y Hemoterapia, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
Barragán E; Servicio de Hematología y Hemoterapia, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
Sargas C; Servicio de Hematología y Hemoterapia, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
Sanz M; Servicio de Hematología y Hemoterapia, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
Martínez-Cuadrón D; Servicio de Hematología y Hemoterapia, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
Montesinos P; Servicio de Hematología y Hemoterapia, Hospital Universitari i Politècnic La Fe, Valencia, Spain. .
Pokaż więcej
Corporate Authors :
PETHEMA group
Źródło :
Annals of hematology [Ann Hematol] 2021 Jun; Vol. 100 (6), pp. 1497-1508. Date of Electronic Publication: 2021 Apr 29.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Multicenter Study
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Hydrazines/*therapeutic use
Leukemia, Myeloid, Acute/*drug therapy
Neoplasm Recurrence, Local/*drug therapy
Triazoles/*therapeutic use
Vidarabine/*analogs & derivatives
Adult ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Cytarabine/administration & dosage ; Cytarabine/adverse effects ; Cytarabine/therapeutic use ; Granulocyte Colony-Stimulating Factor/administration & dosage ; Granulocyte Colony-Stimulating Factor/adverse effects ; Granulocyte Colony-Stimulating Factor/therapeutic use ; Humans ; Hydrazines/administration & dosage ; Hydrazines/adverse effects ; Idarubicin/administration & dosage ; Idarubicin/adverse effects ; Idarubicin/therapeutic use ; Male ; Maximum Tolerated Dose ; Middle Aged ; Treatment Outcome ; Triazoles/administration & dosage ; Triazoles/adverse effects ; Vidarabine/administration & dosage ; Vidarabine/adverse effects ; Vidarabine/therapeutic use
SCR Protocol :
Ida-FLAG protocol
Czasopismo naukowe
Tytuł :
Feasibility of an intensified myeloablative conditioning regimen consisting of busulfan, fludarabine, cytarabine, and total body irradiation before single cord blood transplantation in elderly patients.
Autorzy :
Kawakita T; Department of Hematology, National Hospital Organization Kumamoto Medical Center, 1-5 Ninomaru, Chuo-ku, Kumamoto, 860-0008, Japan. .; Departments of Hematology, Rheumatology, and Infectious Disease, Kumamoto Univerity Graduate School of Medicine, Kumamoto, Japan. .
Hirano T; Department of Hematology, National Hospital Organization Kumamoto Medical Center, 1-5 Ninomaru, Chuo-ku, Kumamoto, 860-0008, Japan.
Inoue Y; Departments of Hematology, Rheumatology, and Infectious Disease, Kumamoto Univerity Graduate School of Medicine, Kumamoto, Japan.
Irie Y; Department of Hematology, National Hospital Organization Kumamoto Medical Center, 1-5 Ninomaru, Chuo-ku, Kumamoto, 860-0008, Japan.
Sugitani H; Department of Hematology, National Hospital Organization Kumamoto Medical Center, 1-5 Ninomaru, Chuo-ku, Kumamoto, 860-0008, Japan.
Kubota A; Department of Hematology, National Hospital Organization Kumamoto Medical Center, 1-5 Ninomaru, Chuo-ku, Kumamoto, 860-0008, Japan.
Watanabe M; Department of Hematology, National Hospital Organization Kumamoto Medical Center, 1-5 Ninomaru, Chuo-ku, Kumamoto, 860-0008, Japan.; Departments of Hematology, Rheumatology, and Infectious Disease, Kumamoto Univerity Graduate School of Medicine, Kumamoto, Japan.
Ueno M; Department of Hematology, National Hospital Organization Kumamoto Medical Center, 1-5 Ninomaru, Chuo-ku, Kumamoto, 860-0008, Japan.; Departments of Hematology, Rheumatology, and Infectious Disease, Kumamoto Univerity Graduate School of Medicine, Kumamoto, Japan.
Mitsui N; Department of Hematology, National Hospital Organization Kumamoto Medical Center, 1-5 Ninomaru, Chuo-ku, Kumamoto, 860-0008, Japan.
Yamaguchi S; Department of Hematology, National Hospital Organization Kumamoto Medical Center, 1-5 Ninomaru, Chuo-ku, Kumamoto, 860-0008, Japan.; Department of Hematology, Arao Municipal Hospital, Kumamoto, Japan.
Inoue Y; Department of Hematology, National Hospital Organization Kumamoto Medical Center, 1-5 Ninomaru, Chuo-ku, Kumamoto, 860-0008, Japan.
Sakai T; Department of Hematology, National Hospital Organization Kumamoto Medical Center, 1-5 Ninomaru, Chuo-ku, Kumamoto, 860-0008, Japan.
Harada N; Department of Hematology, National Hospital Organization Kumamoto Medical Center, 1-5 Ninomaru, Chuo-ku, Kumamoto, 860-0008, Japan.
Matsuoka M; Departments of Hematology, Rheumatology, and Infectious Disease, Kumamoto Univerity Graduate School of Medicine, Kumamoto, Japan.
Hidaka M; Department of Hematology, National Hospital Organization Kumamoto Medical Center, 1-5 Ninomaru, Chuo-ku, Kumamoto, 860-0008, Japan.
Pokaż więcej
Źródło :
International journal of hematology [Int J Hematol] 2021 Jul; Vol. 114 (1), pp. 85-93. Date of Electronic Publication: 2021 Mar 19.
Typ publikacji :
Journal Article
MeSH Terms :
Busulfan/*therapeutic use
Cytarabine/*therapeutic use
Fetal Blood/*transplantation
Myeloablative Agonists/*therapeutic use
Vidarabine/*analogs & derivatives
Aged ; Female ; Graft vs Host Disease/prevention & control ; Humans ; Male ; Middle Aged ; Transplantation Conditioning/methods ; Treatment Outcome ; Vidarabine/therapeutic use ; Whole-Body Irradiation
Czasopismo naukowe
Tytuł :
Fludarabine inhibits type I interferon-induced expression of the SARS-CoV-2 receptor angiotensin-converting enzyme 2.
Autorzy :
Xiu H; Department of Critical Care Medicine, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Gong J; Institute of Immunology, and Department of Orthopaedics of the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Huang T; Department of Critical Care Medicine, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Peng Y; Institute of Immunology, and Department of Orthopaedics of the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Bai S; Department of Critical Care Medicine, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Xiong G; Department of Emergency Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, China.
Zhang S; Department of Cardiology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Huang H; Key Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. .
Cai Z; Institute of Immunology, and Department of Orthopaedics of the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. .
Zhang G; Department of Critical Care Medicine, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. .
Pokaż więcej
Źródło :
Cellular & molecular immunology [Cell Mol Immunol] 2021 Jul; Vol. 18 (7), pp. 1829-1831. Date of Electronic Publication: 2021 May 31.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Angiotensin-Converting Enzyme 2/*biosynthesis
Antiviral Agents/*pharmacology
COVID-19/*drug therapy
Interferon Type I/*pharmacology
Receptors, Virus/*biosynthesis
STAT1 Transcription Factor/*antagonists & inhibitors
Vidarabine/*analogs & derivatives
A549 Cells ; Angiotensin-Converting Enzyme 2/genetics ; Binding Sites ; COVID-19/enzymology ; COVID-19/virology ; Enzyme Induction ; HEK293 Cells ; HeLa Cells ; Humans ; Phosphorylation ; Promoter Regions, Genetic ; Receptors, Virus/genetics ; STAT1 Transcription Factor/metabolism ; Vidarabine/pharmacology
SCR Protocol :
COVID-19 drug treatment
Raport
Tytuł :
Cord blood transplantation with a reduced-intensity conditioning regimen using fludarabine and melphalan for adult T-cell leukemia/lymphoma.
Autorzy :
Nakano N; Department of Hematology, Imamura General Hospital, 11-23 Kamoikeshinmachi, Kagoshima, 890-0064, Japan. .
Takatsuka Y; Department of Hematology, Imamura General Hospital, 11-23 Kamoikeshinmachi, Kagoshima, 890-0064, Japan.
Kubota A; Department of Hematology, Imamura General Hospital, 11-23 Kamoikeshinmachi, Kagoshima, 890-0064, Japan.
Tokunaga M; Department of Hematology, Imamura General Hospital, 11-23 Kamoikeshinmachi, Kagoshima, 890-0064, Japan.
Miyazono T; Department of Hematology, Imamura General Hospital, 11-23 Kamoikeshinmachi, Kagoshima, 890-0064, Japan.
Tabuchi T; Department of Hematology, Imamura General Hospital, 11-23 Kamoikeshinmachi, Kagoshima, 890-0064, Japan.
Odawara J; Department of Hematology, Imamura General Hospital, 11-23 Kamoikeshinmachi, Kagoshima, 890-0064, Japan.
Tokunaga M; Department of Hematology, Imamura General Hospital, 11-23 Kamoikeshinmachi, Kagoshima, 890-0064, Japan.
Makino T; Department of Hematology, Imamura General Hospital, 11-23 Kamoikeshinmachi, Kagoshima, 890-0064, Japan.
Takeuchi S; Department of Hematology, Imamura General Hospital, 11-23 Kamoikeshinmachi, Kagoshima, 890-0064, Japan.
Ito Y; Department of Hematology, Imamura General Hospital, 11-23 Kamoikeshinmachi, Kagoshima, 890-0064, Japan.
Utsunomiya A; Department of Hematology, Imamura General Hospital, 11-23 Kamoikeshinmachi, Kagoshima, 890-0064, Japan.
Pokaż więcej
Źródło :
International journal of hematology [Int J Hematol] 2021 Jun; Vol. 113 (6), pp. 861-871. Date of Electronic Publication: 2021 Feb 16.
Typ publikacji :
Clinical Trial; Journal Article
MeSH Terms :
Cord Blood Stem Cell Transplantation*
Transplantation Conditioning*
Leukemia-Lymphoma, Adult T-Cell/*mortality
Leukemia-Lymphoma, Adult T-Cell/*therapy
Melphalan/*administration & dosage
Vidarabine/*analogs & derivatives
Adult ; Aged ; Allografts ; Disease-Free Survival ; Female ; Humans ; Male ; Middle Aged ; Survival Rate ; Vidarabine/administration & dosage
Czasopismo naukowe
Tytuł :
Haploidentical Stem Cell Transplant With Post Transplant Cyclophosphamide for Chronic Granulomatous Disease With Thiotepa, Busulfan, and Fludarabine as Conditioning.
Autorzy :
Kapoor R; Pediatric Hematology Oncology and Bone Marrow Transplant Unit, Cancer Institute Medanta The Medicity Hospital, Gurgaon Haryana, India.
Rastogi N
Yadav SP
Pokaż więcej
Źródło :
Journal of pediatric hematology/oncology [J Pediatr Hematol Oncol] 2021 May 01; Vol. 43 (4), pp. 155-156.
Typ publikacji :
Case Reports; Letter
MeSH Terms :
Hematopoietic Stem Cell Transplantation*/methods
Busulfan/*therapeutic use
Cyclophosphamide/*therapeutic use
Granulomatous Disease, Chronic/*therapy
Immunosuppressive Agents/*therapeutic use
Thiotepa/*therapeutic use
Vidarabine/*analogs & derivatives
Antineoplastic Agents/therapeutic use ; Child, Preschool ; Humans ; Male ; Transplantation Conditioning/methods ; Transplantation, Haploidentical/methods ; Vidarabine/therapeutic use
Raport
Tytuł :
Fludarabine Inhibits Infection of Zika Virus, SFTS Phlebovirus, and Enterovirus A71.
Autorzy :
Gao C; Jiangsu Key Laboratory of Molecular Medicine, Medical School, Nanjing University, Nanjing 210093, China.
Wen C; Jiangsu Key Laboratory of Molecular Medicine, Medical School, Nanjing University, Nanjing 210093, China.
Li Z; Jiangsu Provincial Center for Disease Control and Prevention, Department of Acute Infectious Diseases Control and Prevention, Nanjing 210009, China.
Lin S; Jiangsu Key Laboratory of Molecular Medicine, Medical School, Nanjing University, Nanjing 210093, China.
Gao S; Jiangsu Key Laboratory of Molecular Medicine, Medical School, Nanjing University, Nanjing 210093, China.
Ding H; Jiangsu Key Laboratory of Molecular Medicine, Medical School, Nanjing University, Nanjing 210093, China.
Zou P; Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
Xing Z; Jiangsu Key Laboratory of Molecular Medicine, Medical School, Nanjing University, Nanjing 210093, China.; Department of Veterinary Biomedical Sciences, College of Veterinary Medicine, University of Minnesota at Twin Cities, Saint Paul, MN 55108, USA.
Yu Y; Jiangsu Key Laboratory of Molecular Medicine, Medical School, Nanjing University, Nanjing 210093, China.
Pokaż więcej
Źródło :
Viruses [Viruses] 2021 Apr 27; Vol. 13 (5). Date of Electronic Publication: 2021 Apr 27.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antiviral Agents/*pharmacology
Enterovirus A, Human/*drug effects
Phlebovirus/*drug effects
Vidarabine/*analogs & derivatives
Zika Virus/*drug effects
Animals ; Antiviral Agents/chemistry ; Cell Line ; Cell Survival ; Cells, Cultured ; Humans ; RNA Viruses/drug effects ; Vidarabine/chemistry ; Vidarabine/pharmacology ; Virus Replication/drug effects
SCR Organism :
SFTS phlebovirus
Czasopismo naukowe
Tytuł :
Predictors of increased melphalan exposure correlate with overall survival, nonrelapse mortality, and toxicities in patients undergoing reduced-intensity allogeneic stem cell transplantation with fludarabine and melphalan.
Autorzy :
Sweiss K; Department of Pharmacy Practice, College of Pharmacy, 14681University of Illinois at Chicago, Chicago, IL, USA.; Cancer Center, University of Illinois, Chicago, IL, USA.
Calip GS; Cancer Center, University of Illinois, Chicago, IL, USA.; Center for Pharmacoepidemiology and Pharmacoeconomic Research, 14681University of Illinois at Chicago, Chicago, IL, USA.
Holden J; Department of Pharmacy Practice, College of Pharmacy, 14681University of Illinois at Chicago, Chicago, IL, USA.
Lewkowski P; Department of Pharmacy Practice, College of Pharmacy, 14681University of Illinois at Chicago, Chicago, IL, USA.
Mialik I; Department of Pharmacy Practice, College of Pharmacy, 14681University of Illinois at Chicago, Chicago, IL, USA.
Johnson J; Department of Pharmacy Practice, College of Pharmacy, 14681University of Illinois at Chicago, Chicago, IL, USA.; Cancer Center, University of Illinois, Chicago, IL, USA.
Galvin JP; Cancer Center, University of Illinois, Chicago, IL, USA.; Division of Hematology/Oncology, 14681University of Illinois at Chicago, Chicago, IL, USA.
Rondelli D; Cancer Center, University of Illinois, Chicago, IL, USA.; Division of Hematology/Oncology, 14681University of Illinois at Chicago, Chicago, IL, USA.
Patel P; Cancer Center, University of Illinois, Chicago, IL, USA.; Division of Hematology/Oncology, 14681University of Illinois at Chicago, Chicago, IL, USA.
Pokaż więcej
Źródło :
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2021 Apr; Vol. 27 (3), pp. 579-587. Date of Electronic Publication: 2020 Jun 03.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents/*administration & dosage
Antineoplastic Agents, Alkylating/*administration & dosage
Melphalan/*administration & dosage
Stem Cell Transplantation/*methods
Vidarabine/*analogs & derivatives
Adult ; Aged ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents, Alkylating/adverse effects ; Antineoplastic Agents, Alkylating/therapeutic use ; Creatinine/metabolism ; Diarrhea/epidemiology ; Female ; Hemoglobins/metabolism ; Humans ; Male ; Melphalan/adverse effects ; Melphalan/therapeutic use ; Middle Aged ; Neoplasms/drug therapy ; Predictive Value of Tests ; Recurrence ; Retrospective Studies ; Survival Analysis ; Transplantation Conditioning ; Treatment Outcome ; Vidarabine/administration & dosage ; Vidarabine/adverse effects ; Vidarabine/therapeutic use ; Young Adult
Czasopismo naukowe
Tytuł :
Comparison of myeloablative and reduced intensity conditioning unrelated donor allogeneic peripheral blood stem cell transplant outcomes for AML using thymoglobulin for GVHD prophylaxis.
Autorzy :
Modi D; Department of Oncology, Karmanos Cancer Institute/Wayne State University, 4100 John R, HW04H0, Detroit, MI, 48201, USA. .
Singh V; Department of Oncology, Karmanos Cancer Institute/Wayne State University, 4100 John R, HW04H0, Detroit, MI, 48201, USA.
Kim S; Biostatistics Core, Karmanos Cancer Institute, Department of Oncology, Wayne State University, Detroit, MI, 48201, USA.
Ayash L; Department of Oncology, Karmanos Cancer Institute/Wayne State University, 4100 John R, HW04H0, Detroit, MI, 48201, USA.
Deol A; Department of Oncology, Karmanos Cancer Institute/Wayne State University, 4100 John R, HW04H0, Detroit, MI, 48201, USA.
Ratanatharathorn V; Department of Oncology, Karmanos Cancer Institute/Wayne State University, 4100 John R, HW04H0, Detroit, MI, 48201, USA.
Uberti JP; Department of Oncology, Karmanos Cancer Institute/Wayne State University, 4100 John R, HW04H0, Detroit, MI, 48201, USA.
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2021 Apr; Vol. 100 (4), pp. 969-978. Date of Electronic Publication: 2021 Feb 16.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Peripheral Blood Stem Cell Transplantation*
Antilymphocyte Serum/*therapeutic use
Busulfan/*therapeutic use
Graft vs Host Disease/*prevention & control
Immunosuppressive Agents/*therapeutic use
Leukemia, Myeloid, Acute/*therapy
Myeloablative Agonists/*therapeutic use
Transplantation Conditioning/*methods
Vidarabine/*analogs & derivatives
Aged ; Allografts ; Busulfan/adverse effects ; Female ; Graft vs Host Disease/etiology ; Humans ; Infections/epidemiology ; Lymphocyte Depletion ; Male ; Middle Aged ; Mycophenolic Acid/therapeutic use ; Myeloablative Agonists/adverse effects ; Progression-Free Survival ; Retrospective Studies ; T-Lymphocytes ; Tacrolimus/therapeutic use ; Treatment Outcome ; Unrelated Donors ; Vidarabine/adverse effects ; Vidarabine/therapeutic use ; Whole-Body Irradiation
Czasopismo naukowe
Tytuł :
Graft-versus-host Disease Prophylaxis With Abatacept Reduces Severe Acute Graft-versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplant for Beta-thalassemia Major With Busulfan, Fludarabine, and Thiotepa.
Autorzy :
Khandelwal P; Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Yeh RF; Division of Pharmacology, Seattle Cancer Care Alliance and Fred Hutchinson Cancer Research Center, Seattle, WA.
Yu L; Division of Pharmacology, Seattle Cancer Care Alliance and Fred Hutchinson Cancer Research Center, Seattle, WA.
Lane A; Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati OH.
Dandoy CE; Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati OH.
El-Bietar J; Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati OH.
Davies SM; Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati OH.
Grimley MS; Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati OH.
Pokaż więcej
Źródło :
Transplantation [Transplantation] 2021 Apr 01; Vol. 105 (4), pp. 891-896.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*/adverse effects
Transplantation Conditioning*/adverse effects
Abatacept/*administration & dosage
Busulfan/*administration & dosage
Graft vs Host Disease/*prevention & control
Immunosuppressive Agents/*administration & dosage
Thiotepa/*administration & dosage
Vidarabine/*analogs & derivatives
beta-Thalassemia/*surgery
Abatacept/adverse effects ; Adolescent ; Busulfan/adverse effects ; Calcineurin Inhibitors/administration & dosage ; Child ; Child, Preschool ; Drug Administration Schedule ; Female ; Graft vs Host Disease/diagnosis ; Graft vs Host Disease/immunology ; Humans ; Immunosuppressive Agents/adverse effects ; Infant ; Male ; Methylprednisolone/administration & dosage ; Retrospective Studies ; Thiotepa/adverse effects ; Time Factors ; Transplantation, Homologous ; Treatment Outcome ; Vidarabine/administration & dosage ; Vidarabine/adverse effects ; beta-Thalassemia/diagnosis
Czasopismo naukowe
Tytuł :
A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia.
Autorzy :
Izutsu K; Department of Hematology, Toranomon Hospital, Tokyo, Japan.; Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Kinoshita T; Department of Hematology/Cell Therapy, Aichi Cancer Center, Nagoya-shi, Japan.
Takizawa J; Department of Hematology/Endocrinology/Metabolism, Faculty of Medicine, Niigata University, Niigata-shi, Japan.
Fukuhara S; Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Yamamoto G; Department of Hematology, Toranomon Hospital, Tokyo, Japan.
Ohashi Y; Faculty of Science and Engineering, Chuo University, Tokyo, Japan.
Suzumiya J; Innovative Cancer Center/Oncology-Hematology, Shimane University Hospital, Izumo-shi, Japan.
Tobinai K; Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
Pokaż więcej
Źródło :
Japanese journal of clinical oncology [Jpn J Clin Oncol] 2021 Mar 03; Vol. 51 (3), pp. 408-415.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Cyclophosphamide/*therapeutic use
Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy
Rituximab/*therapeutic use
Vidarabine/*analogs & derivatives
Aged ; Antibodies, Neoplasm/immunology ; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics ; Area Under Curve ; Cyclophosphamide/adverse effects ; Cyclophosphamide/pharmacokinetics ; Disease Progression ; Endpoint Determination ; Female ; Humans ; Immunosuppression ; Japan ; Leukemia, Lymphocytic, Chronic, B-Cell/blood ; Leukemia, Lymphocytic, Chronic, B-Cell/immunology ; Male ; Middle Aged ; Remission Induction ; Rituximab/adverse effects ; Rituximab/blood ; Rituximab/pharmacokinetics ; Treatment Outcome ; Vidarabine/adverse effects ; Vidarabine/pharmacokinetics ; Vidarabine/therapeutic use
Czasopismo naukowe
Tytuł :
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia.
Autorzy :
Craddock C; Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, United Kingdom.; Cancer Research UK Clinical Trials Unit, University of Birmingham, United Kingdom.
Jackson A; Cancer Research UK Clinical Trials Unit, University of Birmingham, United Kingdom.
Loke J; Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, United Kingdom.
Siddique S; Cancer Research UK Clinical Trials Unit, University of Birmingham, United Kingdom.
Hodgkinson A; Cancer Research UK Clinical Trials Unit, University of Birmingham, United Kingdom.
Mason J; Cancer Research UK Clinical Trials Unit, University of Birmingham, United Kingdom.
Andrew G; Institute of Immunology and Immunotherapy, University of Birmingham, United Kingdom.
Nagra S; Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, United Kingdom.
Malladi R; Addenbrookes Hospital, Cambridge, United Kingdom.
Peniket A; Churchill Hospital, Oxford, United Kingdom.
Gilleece M; St James's Hospital, Leeds, United Kingdom.
Salim R; Royal Liverpool University Hospital, United Kingdom.
Tholouli E; Manchester Royal Infirmary, Manchester, United Kingdom.
Potter V; Kings College Hospital, London, United Kingdom.
Crawley C; Addenbrookes Hospital, Cambridge, United Kingdom.
Wheatley K; Cancer Research UK Clinical Trials Unit, University of Birmingham, United Kingdom.
Protheroe R; Bristol Haematology and Oncology Centre, United Kingdom.
Vyas P; Churchill Hospital, Oxford, United Kingdom.
Hunter A; Leicester Royal Infirmary, United Kingdom.
Parker A; Queen Elizabeth University Hospital, Glasgow, United Kingdom.
Wilson K; University Hospital Wales, United Kingdom.
Pavlu J; Imperial College Hospital, London, Unite Kingdom.
Byrne J; Centre for Clinical Haematology, Nottingham, United Kingdom.
Dillon R; Department of Medical and Molecular Genetics, King's College, London, United Kingdom.
Khan N; Institute of Immunology and Immunotherapy, University of Birmingham, United Kingdom.
McCarthy N; Institute of Immunology and Immunotherapy, University of Birmingham, United Kingdom.
Freeman SD; Institute of Immunology and Immunotherapy, University of Birmingham, United Kingdom.
Pokaż więcej
Źródło :
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2021 Mar 01; Vol. 39 (7), pp. 768-778. Date of Electronic Publication: 2020 Dec 29.
Typ publikacji :
Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Stem Cell Transplantation*/adverse effects
Stem Cell Transplantation*/mortality
Transplantation Conditioning*/adverse effects
Transplantation Conditioning*/mortality
Amsacrine/*administration & dosage
Busulfan/*administration & dosage
Cytarabine/*administration & dosage
Immunosuppressive Agents/*therapeutic use
Leukemia, Myeloid, Acute/*therapy
Myeloablative Agonists/*administration & dosage
Myelodysplastic Syndromes/*therapy
Vidarabine/*analogs & derivatives
Adult ; Aged ; Amsacrine/adverse effects ; Busulfan/adverse effects ; Cytarabine/adverse effects ; Female ; Graft vs Host Disease/etiology ; Graft vs Host Disease/prevention & control ; Humans ; Immunosuppressive Agents/adverse effects ; Leukemia, Myeloid, Acute/mortality ; Leukemia, Myeloid, Acute/pathology ; Male ; Middle Aged ; Myeloablative Agonists/adverse effects ; Myelodysplastic Syndromes/mortality ; Myelodysplastic Syndromes/pathology ; Progression-Free Survival ; Recurrence ; Time Factors ; Transplantation, Homologous ; United Kingdom ; Vidarabine/administration & dosage ; Vidarabine/adverse effects ; Young Adult
Czasopismo naukowe
Tytuł :
Demyelinating brain lesions developing in a patient with chronic lymphocytic leukemia shortly after treatment with a fludarabine containing regimen.
Autorzy :
Kreiniz N; Haematology Unit, Bnai-Zion Medical Centre, Haifa, Israel.
Garty-Ofir M; Neurology Department, Bnai-Zion Medical Centre, Haifa, Israel.; The Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel.
Bejar J; Pathology Department, Bnai Zion Medical Centre, Haifa, Israel.
Polliack A; Haematology Department, Hadassah University Hospital and Hebrew University Medical School, Jerusalem, Israel.
Tadmor T; Haematology Unit, Bnai-Zion Medical Centre, Haifa, Israel.; The Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel.
Pokaż więcej
Źródło :
Hematological oncology [Hematol Oncol] 2021 Feb; Vol. 39 (1), pp. 129-133. Date of Electronic Publication: 2020 Nov 01.
Typ publikacji :
Case Reports
MeSH Terms :
Brain Edema*/chemically induced
Brain Edema*/drug therapy
Brain Edema*/pathology
Demyelinating Diseases*/chemically induced
Demyelinating Diseases*/drug therapy
Demyelinating Diseases*/pathology
Antineoplastic Combined Chemotherapy Protocols/*adverse effects
Leukemia, Lymphocytic, Chronic, B-Cell/*drug therapy
Steroids/*administration & dosage
Vidarabine/*analogs & derivatives
Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Brain/pathology ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/adverse effects ; Female ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/pathology ; Middle Aged ; Rituximab/administration & dosage ; Rituximab/adverse effects ; Vidarabine/administration & dosage ; Vidarabine/adverse effects
Raport
Tytuł :
Hybrid chemotherapy regimen (FLAG-IDA-vincristine-prednisone) for acute leukemia with mixed-phenotype blasts.
Autorzy :
Reid JH; Department of Pharmacy Services and Clinical Pharmacy, Michigan Medicine, USA; University of Michigan College of Pharmacy, USA.
Perissinotti AJ; Department of Pharmacy Services and Clinical Pharmacy, Michigan Medicine, USA; University of Michigan College of Pharmacy, USA.
Benitez LL; Department of Pharmacy Services and Clinical Pharmacy, Michigan Medicine, USA; University of Michigan College of Pharmacy, USA.
Boyer D; Department of Pathology, Michigan Medicine and University of Michigan Medical School, 1500 East Medical Center Drive, Ann Arbor, MI, 48109, USA.
Lee W; Department of Pathology, Michigan Medicine and University of Michigan Medical School, 1500 East Medical Center Drive, Ann Arbor, MI, 48109, USA.
Burke PW; Department of Internal Medicine and Division of Hematology and Oncology, Michigan Medicine and University of Michigan Medical School, 1500 East Medical Center Drive, Ann Arbor, MI, 48109, USA.
Pettit K; Department of Internal Medicine and Division of Hematology and Oncology, Michigan Medicine and University of Michigan Medical School, 1500 East Medical Center Drive, Ann Arbor, MI, 48109, USA.
Bixby DL; Department of Internal Medicine and Division of Hematology and Oncology, Michigan Medicine and University of Michigan Medical School, 1500 East Medical Center Drive, Ann Arbor, MI, 48109, USA.
Marini BL; Department of Pharmacy Services and Clinical Pharmacy, Michigan Medicine, USA; University of Michigan College of Pharmacy, USA. Electronic address: .
Pokaż więcej
Źródło :
Leukemia research [Leuk Res] 2021 Apr; Vol. 103, pp. 106539. Date of Electronic Publication: 2021 Feb 19.
Typ publikacji :
Clinical Trial; Journal Article
MeSH Terms :
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/mortality
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Prednisone/*administration & dosage
Vidarabine/*analogs & derivatives
Vincristine/*administration & dosage
Adult ; Aged ; Cytarabine/administration & dosage ; Disease-Free Survival ; Female ; Granulocyte Colony-Stimulating Factor/administration & dosage ; Humans ; Idarubicin/administration & dosage ; Male ; Middle Aged ; Retrospective Studies ; Survival Rate ; Vidarabine/administration & dosage
SCR Protocol :
Ida-FLAG protocol
Czasopismo naukowe
Tytuł :
Pharmacokinetics of intravenous busulfan as condition for hematopoietic stem cell transplantation: comparison between combinations with cyclophosphamide and fludarabine.
Autorzy :
Kikuchi T; Division of Hematology, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. .
Mori T; Division of Hematology, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Ohwada C; Department of Hematology, Chiba University Hospital, Chiba, Japan.; Department of Hematology, International University of Health and Welfare School of Medicine, Chiba, Japan.
Onoda M; Department of Internal Medicine, Chiba Aoba Municipal Hospital, Chiba, Japan.
Shimizu H; Department of Hematology, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.
Yokoyama H; Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Onizuka M; Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan.
Koda Y; Division of Hematology, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Kato J; Division of Hematology, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Takeda Y; Department of Hematology, Chiba University Hospital, Chiba, Japan.
Hino Y; Department of Hematology, Chiba University Hospital, Chiba, Japan.
Mishina T; Department of Hematology, Chiba University Hospital, Chiba, Japan.
Sakaida E; Department of Hematology, Chiba University Hospital, Chiba, Japan.
Shono K; Department of Internal Medicine, Chiba Aoba Municipal Hospital, Chiba, Japan.
Nagao Y; Department of Internal Medicine, Chiba Aoba Municipal Hospital, Chiba, Japan.
Yokota A; Department of Internal Medicine, Chiba Aoba Municipal Hospital, Chiba, Japan.
Matsumoto K; Department of Clinical Pharmaceutics, Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kyoto, Japan.
Morita K; Department of Clinical Pharmaceutics, Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kyoto, Japan.
Okamoto S; Division of Hematology, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Pokaż więcej
Corporate Authors :
Kanto Study Group for Cell Therapy (KSGCT)
Źródło :
International journal of hematology [Int J Hematol] 2021 Jan; Vol. 113 (1), pp. 128-133. Date of Electronic Publication: 2020 Sep 04.
Typ publikacji :
Comparative Study; Journal Article; Multicenter Study
MeSH Terms :
Busulfan/*administration & dosage
Busulfan/*pharmacokinetics
Cyclophosphamide/*administration & dosage
Hematopoietic Stem Cell Transplantation/*methods
Transplantation Conditioning/*methods
Vidarabine/*analogs & derivatives
Adult ; Age Factors ; Aged ; Cyclophosphamide/pharmacokinetics ; Drug Therapy, Combination ; Female ; Humans ; Male ; Middle Aged ; Prospective Studies ; Transplantation, Homologous ; Treatment Outcome ; Vidarabine/administration & dosage ; Vidarabine/pharmacokinetics ; Young Adult
Czasopismo naukowe
Tytuł :
Gaining insight into irrational off-label use of vidarabine through analysis of a spontaneous reporting system in China.
Autorzy :
Li H; Huaihe Hospital of Henan University, Kaifeng, China.; Institutes of Evidence-Based Medicine and Knowledge Translation, Henan University, Kaifeng, China.
Deng J; Adverse Drug Reaction Monitoring Centre of Guangdong Province, Guangzhou, China.
Yu P; School of Pharmacy, Henan University, Kaifeng, China.
Deng L; Adverse Drug Reaction Monitoring Centre of Guangdong Province, Guangzhou, China.
Ren X; Huaihe Hospital of Henan University, Kaifeng, China.; Institutes of Evidence-Based Medicine and Knowledge Translation, Henan University, Kaifeng, China.
Pokaż więcej
Źródło :
Journal of clinical pharmacy and therapeutics [J Clin Pharm Ther] 2020 Dec; Vol. 45 (6), pp. 1301-1311. Date of Electronic Publication: 2020 Jul 02.
Typ publikacji :
Journal Article
MeSH Terms :
Adverse Drug Reaction Reporting Systems/*statistics & numerical data
Antiviral Agents/*adverse effects
Inappropriate Prescribing/*statistics & numerical data
Vidarabine/*adverse effects
Adolescent ; Adult ; Age Factors ; Aged ; Antiviral Agents/administration & dosage ; Child ; Child, Preschool ; China ; Female ; Humans ; Infant ; Infant, Newborn ; Male ; Middle Aged ; Off-Label Use/standards ; Vidarabine/administration & dosage ; Young Adult
Czasopismo naukowe
Tytuł :
Sequential treatment with FLAG-IDA/treosulfan conditioning regimen for patients with active acute myeloid leukemia.
Autorzy :
Shargian-Alon L; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, 49100, Petah-Tikva, Israel. .; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. .
Wolach O; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, 49100, Petah-Tikva, Israel.; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Rozovski U; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, 49100, Petah-Tikva, Israel.; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Yahav D; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.; Infectious Disease Unit, Rabin Medical Center, Petah-Tikva, Israel.
Sela-Navon M; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, 49100, Petah-Tikva, Israel.
Rubinstein M; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, 49100, Petah-Tikva, Israel.
Oniashvilli N; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.; The Raphael Recanati Genetic Institute, Rabin Medical Center, Petah-Tikva, Israel.
Pasvolsky O; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, 49100, Petah-Tikva, Israel.; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Raanani P; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, 49100, Petah-Tikva, Israel.; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Yeshurun M; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, 49100, Petah-Tikva, Israel.; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2020 Dec; Vol. 99 (12), pp. 2939-2945. Date of Electronic Publication: 2020 Sep 06.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents, Alkylating/*administration & dosage
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Busulfan/*analogs & derivatives
Leukemia, Myeloid, Acute/*diagnosis
Leukemia, Myeloid, Acute/*therapy
Transplantation Conditioning/*methods
Vidarabine/*analogs & derivatives
Adult ; Aged ; Busulfan/administration & dosage ; Cohort Studies ; Cytarabine/administration & dosage ; Disease-Free Survival ; Female ; Granulocyte Colony-Stimulating Factor/administration & dosage ; Humans ; Idarubicin/administration & dosage ; Leukemia, Myeloid, Acute/mortality ; Male ; Middle Aged ; Retrospective Studies ; Treatment Outcome ; Vidarabine/administration & dosage ; Young Adult
SCR Protocol :
Ida-FLAG protocol
Czasopismo naukowe
Tytuł :
Improving survival rates for patients with acute myeloid leukemia: Impacts of fludarabine/busulfan and antithymocyte globulin as reduced toxicity myeloablative conditioning for matched related donor allo-HCT.
Autorzy :
Yafour N; Service d'hématologie et de thérapie cellulaire, établissement hospitalier et universitaire 1er Novembre 1954, BP 4166, 31000 Ibn Rochd, Oran, Algeria; Université d'Oran 1, Ahmed Ben Bella, faculté de médecine, Oran, Algeria. Electronic address: .
Serradj F; Service d'hématologie et de thérapie cellulaire, établissement hospitalier et universitaire 1er Novembre 1954, BP 4166, 31000 Ibn Rochd, Oran, Algeria; Université d'Oran 1, Ahmed Ben Bella, faculté de médecine, Oran, Algeria. Electronic address: .
Osmani S; Service d'hématologie et de thérapie cellulaire, établissement hospitalier et universitaire 1er Novembre 1954, BP 4166, 31000 Ibn Rochd, Oran, Algeria; Université d'Oran 1, Ahmed Ben Bella, faculté de médecine, Oran, Algeria. Electronic address: .
Brahimi M; Service d'hématologie et de thérapie cellulaire, établissement hospitalier et universitaire 1er Novembre 1954, BP 4166, 31000 Ibn Rochd, Oran, Algeria; Université d'Oran 1, Ahmed Ben Bella, faculté de médecine, Oran, Algeria. Electronic address: .
Bouhass R; Service d'hématologie et de thérapie cellulaire, établissement hospitalier et universitaire 1er Novembre 1954, BP 4166, 31000 Ibn Rochd, Oran, Algeria; Université d'Oran 1, Ahmed Ben Bella, faculté de médecine, Oran, Algeria. Electronic address: .
Arabi A; Service d'hématologie et de thérapie cellulaire, établissement hospitalier et universitaire 1er Novembre 1954, BP 4166, 31000 Ibn Rochd, Oran, Algeria; Université d'Oran 1, Ahmed Ben Bella, faculté de médecine, Oran, Algeria. Electronic address: .
Bazarbachi A; American University of Beirut, Medical Center, 113-6044, Beirut, Lebanon. Electronic address: .
Bekadja MA; Service d'hématologie et de thérapie cellulaire, établissement hospitalier et universitaire 1er Novembre 1954, BP 4166, 31000 Ibn Rochd, Oran, Algeria; Université d'Oran 1, Ahmed Ben Bella, faculté de médecine, Oran, Algeria. Electronic address: .
Pokaż więcej
Źródło :
Current research in translational medicine [Curr Res Transl Med] 2020 Nov; Vol. 68 (4), pp. 145-148. Date of Electronic Publication: 2020 Oct 04.
Typ publikacji :
Letter
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Leukemia, Myeloid, Acute*/drug therapy
Vidarabine/*analogs & derivatives
Antilymphocyte Serum/administration & dosage ; Busulfan/administration & dosage ; Humans ; Survival Rate ; Transplantation Conditioning ; Vidarabine/therapeutic use
Opinia redakcyjna
Tytuł :
[Cutaneous complications following hematopoietic stem cell transplantation].
Autorzy :
Araqi Houssaini L; CHU Ibn Rochd, service de dermatologie et de vénérologie, 1, rue des Hôpitaux, Casablanca, Maroc. Electronic address: .
Hali F; CHU Ibn Rochd, service de dermatologie et de vénérologie, 1, rue des Hôpitaux, Casablanca, Maroc.
Quessar A; Hôpital 20 Août, service d'hématologie, 6, rue Lahcen Al Aarjoune, Casablanca, Maroc.
Marnissi F; CHU Ibn Rochd, service d'anatomie pathologique, 1, rue des Hôpitaux, Casablanca, Maroc.
Chiheb S; CHU Ibn Rochd, service de dermatologie et de vénérologie, 1, rue des Hôpitaux, Casablanca, Maroc.
Pokaż więcej
Transliterated Title :
Complications cutanées post-allogreffe de cellules souches hématopoïétiques.
Źródło :
Bulletin du cancer [Bull Cancer] 2021 Sep; Vol. 108 (9), pp. 877-885. Date of Electronic Publication: 2021 Jul 08.
Typ publikacji :
Journal Article
MeSH Terms :
Hematologic Diseases/*therapy
Hematopoietic Stem Cell Transplantation/*adverse effects
Skin Diseases/*etiology
Acute Disease ; Adolescent ; Adult ; Allografts ; Busulfan/therapeutic use ; Candidiasis/diagnosis ; Chickenpox/diagnosis ; Child ; Chronic Disease ; Dermatomycoses/diagnosis ; Dermatomycoses/microbiology ; Female ; Graft vs Host Disease/diagnosis ; Herpes Genitalis/diagnosis ; Humans ; Induction Chemotherapy/methods ; Malassezia ; Male ; Melphalan/therapeutic use ; Middle Aged ; Morocco ; Prospective Studies ; Skin Diseases/pathology ; Skin Diseases, Infectious/diagnosis ; Vidarabine/analogs & derivatives ; Vidarabine/therapeutic use ; Young Adult
Czasopismo naukowe
Tytuł :
A Screening of Antineoplastic Drugs for Acute Myeloid Leukemia Reveals Contrasting Immunogenic Effects of Etoposide and Fludarabine.
Autorzy :
Ocadlikova D; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Istituto di Ematologia 'Seràgnoli', Università degli Studi, 40138 Bologna, Italy.; Azienda Ospedaliero-Universitaria di Bologna, via Albertoni 15, 40138 Bologna, Italy.
Iannarone C; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Istituto di Ematologia 'Seràgnoli', Università degli Studi, 40138 Bologna, Italy.
Redavid AR; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Istituto di Ematologia 'Seràgnoli', Università degli Studi, 40138 Bologna, Italy.
Cavo M; Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Istituto di Ematologia 'Seràgnoli', Università degli Studi, 40138 Bologna, Italy.; Azienda Ospedaliero-Universitaria di Bologna, via Albertoni 15, 40138 Bologna, Italy.
Curti A; Azienda Ospedaliero-Universitaria di Bologna, via Albertoni 15, 40138 Bologna, Italy.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2020 Sep 16; Vol. 21 (18). Date of Electronic Publication: 2020 Sep 16.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents/*pharmacology
Etoposide/*pharmacology
Immunogenic Cell Death/*drug effects
Leukemia, Myeloid, Acute/*drug therapy
Vidarabine/*analogs & derivatives
Adenosine Triphosphate/metabolism ; Alarmins/metabolism ; Antineoplastic Agents/administration & dosage ; Calreticulin/metabolism ; Cell Line, Tumor ; Cytarabine/administration & dosage ; Cytarabine/pharmacology ; Daunorubicin/administration & dosage ; Daunorubicin/pharmacology ; Dendritic Cells/immunology ; Etoposide/administration & dosage ; Extracellular Space ; Gene Expression Regulation, Neoplastic/drug effects ; Heat-Shock Proteins/metabolism ; Humans ; Leukemia, Myeloid, Acute/immunology ; Lymphocyte Activation ; Neoplasm Proteins/genetics ; Neoplasm Proteins/metabolism ; Organelles/metabolism ; Protein Transport/drug effects ; T-Lymphocyte Subsets/immunology ; Vidarabine/administration & dosage ; Vidarabine/pharmacokinetics
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies